Loading…
MINT-DUTASTERIDE is a brand name for Dutasteride, supplied as a capsule. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE .............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS…
Verbatim from this product's HC label. Tap a section to expand.
5 mg capsule taken orally once a day. 4 mg capsule taken once daily. Administration MINT-DUTASTERIDE should be swallowed whole and not chewed or opened, as contact with the capsule contents may result in irritation of the oropharyngeal mucosa.
(See WARNINGS AND PRECAUTIONS, Exposure of Women - Risk to Male Fetus and SPECIAL HANDLING INSTRUCTIONS). MINT-DUTASTERIDE may be taken with or without food (see WARNINGS AND PRECAUTIONS, Drug-Food Interactions). Although an improvement in symptoms may be observed after 3 months in some patients, it can take up to 6 months before a response to the treatment can be achieved (See CLINICAL TRIALS).
Renal Impairment The effect of renal impairment on dutasteride pharmacokinetics has not been studied. 5 mg dose of dutasteride is recovered in human urine, and no adjustment in dose is anticipated for patients with renal impairment.
Hepatic Impairment The effect of hepatic impairment on dutasteride pharmacokinetics has not been studied. Because dutasteride is extensively metabolized and has a half-life of 3 to 5 weeks, caution should be used in the administration of dutasteride to patients with liver disease.
Page 17 of 50 Missed Dose If a dose is missed the capsule can be taken at the next scheduled dose. Extra capsules taken for missed doses are not necessary. OVERDOSAGE In volunteer studies of dutasteride, single daily doses of dutasteride up to 40 mg/day (80 times the therapeutic dose) have been administered for 7 days without significant safety concerns.
5 mg. There is no specific antidote for MINT-DUTASTERIDE. Therefore, in cases of suspected overdosage, symptomatic and supportive treatment should be given as appropriate, taking the long half-life of dutasteride in consideration. ACTION AND CLINICAL PHARMACOLOGY Mechanism of Action Dutasteride, a synthetic 4-azasteriod compound, inhibits the conversion of testosterone to 5α- dihydrotestosterone (DHT).
DHT is the androgen primarily responsible for the initial development and subsequent enlargement of the prostate gland. Testosterone is converted to DHT by the enzyme 5 α-reductase, which exists as 2 isoforms, Type I and Type II. Both Type I and Type II isoenzymes are present in the prostate.
The Type I isoenzyme is also responsible for testosterone conversion in the skin and liver. It has been observed that compared to normal tissue, the expression of both isoenzymes are increased in BPH tissue. Dutasteride is a competitive and specific inhibitor of both Type I and Type II 5α-reductase isoenzymes, with which it forms a stable enzyme complex.
MINT-DUTASTERIDE is contraindicated for use in women and children (see WARNINGS AND PRECAUTIONS, Exposure of Women-Risk to Male Fetus). MINT-DUTASTERIDE is contraindicated in patients with known hypersensitivity to dutasteride, other 5 alpha-reductase inhibitors, or any component of the preparation.
WARNINGS AND PRECAUTIONS General Increased Risk of High-grade Prostate Cancer:
Prior to treatment with MINT- DUTASTERIDE, patients should be assessed thoroughly to rule out other urological diseases including prostate cancer. MINT-DUTASTERIDE may be associated with an increase in high grade prostate cancer. 0 ng/mL, taking MINT-DUTASTERIDE for 4 years, there was an increased incidence of Gleason score 8-10 prostate cancer compared with men taking placebo (see ADVERSE REACTIONS).
At this time it is unknown how therapy with MINT- DUTASTERIDE might influence the progression of prostate cancer or affect high grade prostate cancer. No causal relationship between MINT-DUTASTERIDE and high grade prostate cancer has been established.
1%). 5 alpha-reductase inhibitors may increase the risk of development of high-grade prostate cancer. Whether the effect of 5 alpha-reductase inhibitors to reduce prostate volume, or study related factors, impacted the results of these studies has not been established.
See INDICATION AND CLINICAL USE and ADVERSE REACTIONS. Breast changes including breast enlargement, tenderness and cancer have been reported. Prescribers should instruct their patients to promptly report any changes in their breast tissue such as lumps or nipple discharge (see ADVERSE REACTIONS).
Patients with a large residual urinary volume and/or severely diminished urinary flow may not be proper candidates for 5 alpha-reductase inhibitor therapy and should be carefully monitored for obstructive uropathy. Serious Warnings and Precautions MINT-DUTASTERIDE is for use for men only.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Dutasteride in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Dissociation from this complex has been evaluated under in vitro and in vivo conditions and is extremely slow. Dutasteride lowers DHT levels and leads to a reduction in prostatic volume, thereby treating an underlying cause of BPH. Dutasteride does not bind to the human androgen receptor.
Pharmacodynamics The maximum effect of daily doses of dutasteride on the reduction on DHT is dose dependent and is observed within 1-2 weeks. 5 mg, median serum DHT concentrations were reduced by 85% and 90% respectively. For management of a suspected drug overdose, contact your regional Poison Control Centre.
5 mg/day for 4 years, the median decrease in serum DHT was 94% at 1 year, 93% at 2 years, and 95% at both 3 and 4 years. The median increase in serum testosterone was 19% at both 1 and 2 years, 26% at 3 years, and 22% at 4 years. The testosterone concentrations remain within the physiological normal range.
001). 001). 001). In another study, men with localized prostate cancer received a loading dose of dutasteride 10 mg/day for 7 days followed by dutasteride 5 mg/day for up to 10 weeks prior to radical prostatectomy, Mean DHT concentrations in prostatic tissue were substantially lower in the dutasteride group compared with placebo (177 and 6,179 pg/g, respectively).
Pharmacokinetics Absorption:
Dutasteride is rapidly absorbed with peak concentrations occurring at 1 to 3 hours and absorption is not affected by food. Absolute bioavailability is approximate 60% relative to a 2-hour intravenous infusion. 5%). The half-life of dutasteride is 3 to 5 weeks.
5 mg once daily. Similarly, dutasteride concentrations in semen reached steady- state at 6 months. 4 to 14 ng/mL). Metabolism: […]
Exposure of Women-Risk to Male Fetus:
Dutasteride is absorbed through the skin. Therefore, women who are pregnant or may be pregnant should not handle MINT-DUTASTERIDE. Page 5 of 50 No study has been conducted to determine if MINT-DUTASTERIDE can be used for the control of BPH in asymptomatic patients.
The long-term (> 4 years) beneficial and adverse effects of MINT-DUTASTERIDE have not been established. Cardiovascular In two 4-year clinical studies, the incidence of cardiac failure (a composite term of reported events, primarily cardiac failure and congestive cardiac failure) was higher among subjects taking the combination of dutasteride and an alpha-blocker, primarily tamsulosin, than it was among subjects not taking the combination.
07] compared with tamsulosin monotherapy. In these 2 studies, the incidence of cardiac failure was low (≤ 1%) and variable between the studies. No imbalance was observed in the incidence of cardiovascular adverse events overall in either study.
While no causal relationship between MINT-DUTASTERIDE (alone or in combination with an alpha- blocker) and cardiac failure has been established, patients with underlying risk factors for cardiovascular disease, including past or current cardiovascular conditions, advanced age, elevated resting heart rate, should be monitored for signs and symptoms of cardiac failure (see ADVERSE REACTIONS).
5 mg/day (n = 26) resulted in no clinically significant change compared with placebo (n = 23) in sex hormone binding globulin, estradiol, luteinizing hormone, follicle-stimulating hormone, thyroxine (free T4), and dehydroepiandrosterone.
05). 4% for TSH at 52 weeks. After stopping dutasteride for 24 weeks, the mean levels of testosterone and TSH had returned to baseline in the group of subjects with available data at the visit. 5 mg/day for 4 years, the median decrease in serum DHT was 94% at 1 year, 93% at 2 years, and 95% at both 3 and 4 years.
The median increase in serum testosterone was 19% at both 1 and 2 years, 26% at 3 years, and 22% at 4 years, but the mean and median levels remained within the physiologic range. In patients with BPH treated with dutasteride in a large Phase III trial, there was a median percent increase in luteinizing hormone of 12% at 6 months and 19% at both 12 and 24 months.
Hematologic Men treated with dutasteride should not donate blood until at least 6 months have passed following their last dose. The purpose of this deferred period is to prevent administration of dutasteride to a pregnant female transfusion recipient.
Page 6 of 50 Hepatic The effect of hepatic impairment on dutasteride pharmacokinetics has not been studied. Because dutasteride is extensively metabolized and has a half-life of 3 to 5 weeks, caution should be used in the administration of dutasteride to patients with liver disease.
5 mg/day on semen characteristics were evaluated in normal volunteers aged 18 to 52 (n=27 dutasteride, n=23 placebo) throughout 52 weeks of treatment and 24 weeks of post treatment […]